DOCSLIB.ORG

2015 AB 128 Code of Conduct Compliant Companies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2015 AB 128 Code of Conduct Compliant Companies Nevada AB128 Compliant Companies Abbott Diabetes Care Division 454 Life Sciences 50 Industrial Rd. Branford CT 06405 Abbott Diagnostic Division Abbott Electrophysiology Abbott Electrophysiology (Topera, Inc. December 2014) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Point of Care Division Abbott Vascular Division AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis Pharma, Inc. A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc. Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn Sales, Inc. Akorn, Inc. 1925 WestField Court, Suite 300 Lake Forest IL 60045 Akrimax Pharmaceuticals, LLC 11 Commerce Drive, 1st Floor Cranford NJ 07016 Alamo Pharma Services, Inc. Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alimera Sciences, Inc. 6120 Windward Parkway, Suite 290 Alpharetta GA 30005 Alkermes, Inc. 852 Winter Street Waltham MA 02451 Allen Medical Systems, Inc. 825 Winter Waltham MA 02461 Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Alliqua BioMedical, Inc. 2150 Cabot Blvd, West Suite B Langhorne PA 19047 Allos Therapeutics, Inc Alverix, Inc. 3/30/2016 Page 1 of 17 Nevada AB128 Compliant Companies AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham MA 02451 Amarin Pharmaceuticals AMATECH Corporation Amazonian Region Botanical Products, LLC Amedra Pharmaceuticals, LLC (March 10, 2015) American Homecare Federation 31 Moody Rd Enfield CT 06083 American Homecare Federation 95 E. Ashley Ave. West Springfield WA 01089 American Medical Electonics, Inc. 3451 Plano Parkway Lewisville TX 75056 American Regent, Inc. Amerisource Health Services Corp (dba American Health Packaging) 2550 John Glenn Ave, Suite A Columbus OH 43217 AmerisourceBergan Corporation 5100 Jaindl Blvd. Bethlehem PA 43137 AmerisourceBergan Corporation 1325 West Striker Ave. Sacramento CA 95834 AmerisourceBergan Drug Corporation 1851 California Ave. Corona CA 92881 AmerisourceBergen Corporation 1300 Morris Drive Chesterbrook PA 19087 AmerisourceBergen Drug Corporation 6305 LaSalle Drive Lockbourne OH 43137 AmerisourceBergen Drug Corporation 1825 S 43rd Avenue, Suite B Phoenix AZ 95009 AmerisourceBergen Drug Corporation 1765 Fremont Drive Salt Lake City UT 84104 Amgen, Inc. 1 Amgen Center Drive Thousand Oaks CA 91320 Amgen, USA Amphastar Pharmaceuticals, Inc. 11570 Sixth St. Rancho Cucamnga CA 91730 Anda, Inc. Animas Corporation Apollo Endosurgery, Inc. 1120 S Capital of TX Hwy, Bldg 1, ste 300 Austin TX 78746 ApoPharma USA Inc. 9605 Medicl Center Dr., Suite 390 Rockville MD 20850 Applied Medical Distribution Corporation 22872 Avenida Empress Rancho Santa Margarita CA 92688 Applied Medical Resources Corporation 22872 Avenida Empress Rancho Santa Margarita CA 92688 Apria Healthcare, Inc 26220 Enterprise Court Lake Forest CA 92630 Aptalis Pharmaca US, Inc. Aribex, Inc. 1717 West Collins Avenue Orange CA 92867 Ariosa Aristos Pharmceuticals ARKRAY AMERICA, INC 5298 W. 76th Street Minneapolis MN 55439 ARKRAY FACTORY USA, INC ARKRAY USA, INC Armstrong Pharmaceuticals, Inc. Arthrex, Inc. 1370 Creekside Blvd Naples FL 34108 Ascend Therapeutics, US LLC 607 Herndon Parkway, Suite 110 Herndon VA 20170 Ascension Orthopedics, Inc. ASD Specialty Healthcare, Inc. 345 International Boulvard, Suite 400 Brooks KY 40109 ASD Specialty Healthcare, Inc. 5360 Capital Court, Suite 102 Reno NV 89502 ASD Specialty Healthcare, Inc. 1195 Trademark Dr, 102A Reno NV 89521 Aspen Surgical Products Holdings, Inc. Aspen Surgical Products Holdings, Inc. 3/30/2016 Page 2 of 17 Nevada AB128 Compliant Companies Aspen Surgical Products, Inc. Astellas Pharma US, Inc. Three Parkway North Deerfield IL 60015 Asthmatx, Inc. AstraZenca LP 1800 Concord Pike Wilmington DE 19850 AstraZenca Pharmaceuticals LP 1800 Concord Pike Wilmington DE 19850 Astute Medical, Inc. 3550 General Atomics Court San Diego CA 92121 At Home IV Infusion Professional, Inc. 6925 Oakland Mills Rd., Suite D Columbia MD 21045 Aton Pharma, Inc. Atos Medical, Inc. 11390 W Theodore Trecker Way West Allis WI 53214 Atrium Medical Corp. Atto BioScience, Inc. Audrey Enterprise, LLC Auxilium Pharmaceuticals, Inc. 640 Lee Road Chesterbrook PA 19087 Avanir Pharmaceuticals, Inc. 101 Enterprise Aliso Viejo CA 92694 Avid Radiopharmaceuticals, Inc. Avinger, Inc. 400 Chesapeake Drive Redwood City CA 94063 Azeo Processing, Inc. B&B Pharmaceuticals, Inc. 8591 Prairie Train Drive Ste C-60- Emg;ewppd CO 80112 B. Braun Interventional Systems, Inc. 824 Twelfth Avenue Bethlehem PA 18018 B. Braun Medical, Inc. 824 Twelfth Avenue Bethlehem PA 18018 B+L Diagnostics, Inc. Banyan International Corp. 2118 E. Interstate 20 Abilene TX 79604 Banyan International Corp. 2118 E. Interstate 20 Abilene TX 79604 Bard Access Systems, Inc. Bard Peripheral Vascular, Inc. Bausch & Lomb Holdings Incorporation Bausch & Lomb Pharma Holdings Corp Baush & Lomb (Jersey) Limited Baush & Lomb China, Inc. Baush & Lomb Incorporated Baush & Lomb International Inc. Baush & Lomb Realty Corporation Baush & Lomb South Asia, Inc. Baush & Lomb Technology Corporation Baxter Healthcare Corporation One Baxter Parkway Deerfield IL 60015 Bayer Healthcare LLC, Animal Health Division Bayer Healthcare LLC, Consurmer Care Division Bayer Healthcare LLC. 6 West Belt Wayne IN 07470 Bayer Healthcare Pharmaceuticals, Inc. Bayer LLC, Dermatological Divison Bayer LLC, Diabetes Care Division Bayer LLC, Radiology & Interventional BD AcuteCare, Inc. 3/30/2016 Page 3 of 17 Nevada AB128 Compliant Companies BD Biosciences Sys & Reagents, Inc. BD Infusion Therapy Systems, Inc. BD Rx Becton Dickinson and Company and subsidiaries 1 Becton Drive Franklin Lakes NJ 07417 Bellco Drug Corp. 5500 New Horizons Blvd. N Amityville NY 11701 Bina Biocomp Pharma, Inc. BioCSL, Inc. (CSL Biotherapies Inc.) BioMarin Pharmaceutical, Inc. 105 Digital Drive Novato CA 94949 Biomet 3i, LLC Biomet Biologics, LLC Biomet Manufacturing, LLC Biomet Microfixation, LLC Biomet Orthopedics, LLC Biomet Spine and Bone Healing Technologies, LLC Biomet Sports Medicine, LLC Biomet Trauma, LLC Biomet, Inc. 56 E. Bell Drive Warsaw IN 46581 BioRx, LLC 10828 Kenwood Road Cincinnati OH 45242 BioRx, LLC 1819 Aston St, Suite 102 Carlsbad CA 92008 BioRx, LLC 7167 E. Kemper Road Cincinnati OH 45249 BioRx, LLC 8690 Eagle Creek Parkway Savage MN 55378 BioRx, LLC 9045 E. Pima Center Parkway Scottsdale AZ 85258 BioRx, LLC 3821 71 St. Suite C Urbandale IA 50322 BioRx, LLC 266 West Cummings Park Woburn MA 01801 BioRx, LLC 4004 Spring Garden St, Suite D Greensboro NC 27407 Biosense Webster, Inc 3333 Diamond Canyon Road Bridgewaer NJ 08807 Biotest Pharmaceuticals Corporation 5800 Park of Commerce Blvd. NW Boca Raton FL 33487 Biovail Americas Corp. Biovail NTI Inc. Bioventus LLC 3303 E. Holmes Road Memphis TN 38118 Blackstone Medical, Inc. 3451 Plano Parkway Lewisville TX 75056 Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Rd. Ridgefield CT 06877 Boston Scientific Corporation One Boston Scientific Place Natick MA 01760 Boston Scientific Neuromodulation Brainlab, Inc. 3 Westbrook Corporate Center, Suite 400 Westchester IL 60154 Braintree Laboratories, Inc. 60 Columbian Street West Braintree MA 02185 Bristol-Myers Squibb Company 777 Scudders Mill Road Plainsboro NJ 08536 Bryant Ranch Prepack 12623 Sherman Way #A North Hollywood CA 91605 BS Scimed, Inc. Burman's Apothecary dba Burman's Specialty Pharmacy 3413 Edgmont Ave, Suite B Brookhaven PA 19015 Burman's Media Pharmacy LLC 594 New Middletown Media PA 19063 Butler Animal Health Supply, LLC 400 Metro Place North Dublin OH 43017 3/30/2016 Page 4 of 17 Nevada AB128 Compliant Companies C.R. Bard, Inc. 730 Central Avenue Murray Hill NJ 07974 Cadence Pharmaceuticals, Inc. 12481 High Bluff, Suite 200 San Diego CA 92130 Cameron Health, Inc. Cangene Corporation 920 Cassatt Rd. Suite 100 Bernyn PA 19312 Cantel Medical Corp. 150 Clove Road, 9th florr Little Falls NJ 7424 Cardiac Packemakers, Inc. Cardinal Health, Inc. and It's subsidiaries 7000 Cardinal Place Dublin OH 43017 CareFusion Corporation 3750 Torrey View Ct. San Diego CA 92130 Carestream Dental, LLC 1765 The Exchange SE Atlanta GA 30339 Carestream Health,Inc 150 Verona Street Rochester NY 14608 Carl Zeiss Meditec, Inc. 5160 Hacienda Drive Dublin CA 94568 Carmel Pharma AB Celera Corportation 1401 Harbor Bay Parkway Alameda CA 94502 Celgene Corporation 86 Morris Avenue Summitt NJ 07901 Centerix Orthopaedics, Inc. 959 Hamilton Ave Menlo Park CA 94025 Centinel Spine, Inc. 505 Park Ave, 14th floor New York NY 10022 Central Admixture Pharmacy Services, Inc. 824 Twelfth Avenue Bethlehem PA 18018 Chiesi USA, Inc. 1255 Crescent Green Drive, Suite250 Cary NC 27519 Citra Labs, LLC Clarity Medical Systems 5775 W. Las Positas Blvd
Load more

Recommended publications
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds
    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
    [Show full text]
  • Transcept Pharmaceuticals, Inc
    Table of Contents SCHEDULE 14A (RULE 14A 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by x Definitive Proxy Statement Rule 14a-6(e)(2)) ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Transcept Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 23, 2011 To Our Stockholders: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Transcept Pharmaceuticals, Inc., a Delaware corporation, will be held on Thursday, June 23, 2011, at 8:30 a.m., local time, at our office located at 1003 West Cutting Blvd., Suite 110, Point Richmond, California 94804, for the following purposes: 1.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/22/13 for the Period Ending 12/30/12 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/12 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2012 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • Advances in Management of Diabetic Retinopathy Featuring the P
    Advances in Management of Diabetic Retinopathy featuring the P. Kenneth Nase Memorial Lecture (05/22/21 @ 8 a.m. ET) Saturday, May 22, 2021 Online Name of commercial interest/Nature Name of individual Individual's role in activity of relationship Grant / Research Support-Apellis Pharmaceuticals|Grant / Research Support-Genentech|Consultant / Independent Contractor-Apellis Allen Chiang, MD Faculty Pharmaceuticals|Grant / Research Support-Regeneron|Consultant / Independent Contractor-Orbit Biomedical - 03/19/2021 Consultant / Independent Contractor- Michael N Cohen, MD Faculty Allergan|Consultant / Independent Contractor-Keeler, Inc. - 05/04/2021 Consultant / Independent Contractor- Deciphera|Consultant / Independent Contractor-Bausch & Lomb|Consultant / Independent Contractor-Johnson and Johnson|Consultant / Independent Sunir J. Garg, MD Faculty Contractor-Allergan|Grant / Research Support-Regeneron|Grant / Research Support-Apellis|Grant / Research Support-Boehringer Ingelheim - 02/24/2021 Omesh Gupta, MD Faculty Nothing to disclose - 03/21/2021 Advisor / Board Member-IVERIC Bio|Grant / Research Support-IVERIC Bio|Consultant / Independent Contractor-Gyroscope Jason Hsu, MD Faculty Therapeutics|Consultant / Independent Contractor-OccuRx|Grant / Research Support-Genentech|Grant / Research Support-Aldeyra Therapeutics - 03/20/2021 Consultant / Independent Contractor- Allergan|Consultant / Independent M. Ali Khan, MD Faculty Contractor-Apellis Pharmaceuticals|Consultant / Independent Contractor- Genentech|Grant / Research Support- Regeneron
    [Show full text]
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
    [Show full text]
  • CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 CONCERT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Concert Pharmaceuticals, Inc.
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • 2020-2021 Cancer Communications Committee Disclosures All Relationships Are Considered Compensated
    2020-2021 Cancer Communications Committee Disclosures All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Name EMAIL Committee Employment Leadership Stock and Other Honoraria Consulting or Advisory Speakers' Bureau Research Funding Patents, Royalties, Other Expert Testimony Travel, Other Relationship (OPTIONAL) (OPTIONAL) Open Member Status Ownership Interests Role Intellectual Property Accommodations, Uncompensated Payments Link Expenses Relationships Neeraj Agarwal [email protected] Active Astellas Pharma Active Biotech (Inst) Astellas Pharma Amgen (Inst) AstraZeneca AstraZeneca (Inst) AstraZeneca Bavarian Nordic (Inst) AVEO Bayer (Inst) Bayer BN ImmunoTherapeutics Bristol-Myers Squibb (Inst) Calithera Biosciences Bristol-Myers Squibb (Inst) Eisai Calithera Biosciences EMD Serono (Inst) Exelixis Celldex (Inst) Foundation Medicine Eisai (Inst) Foundation One Inc Exelixis (Inst) Genentech Genentech (Inst) Janssen Oncology GlaxoSmithKline (Inst) Lilly Immunomedics (Inst) Lilly Janssen (Inst) lily Merck (Inst) Medivation/Astellas Newlink Genetics (Inst) MEI Pharma Novartis (Inst) Merck Pfizer (Inst) Nektar Prometheus (Inst) Novartis Rexahn Pharmaceuticals Pfizer (Inst) Pfizer Sanofi (Inst) Pharmacyclics Takeda (Inst) Seattle Genetics TRACON Pharma (Inst) Muhammad S. Beg muhammad.beg@utsouthwestern. Active Array BioPharma Agios (Inst) edu AstraZeneca/MedImmune ArQule (Inst) Cancer Commons AstraZeneca/MedImmune Ipsen (Inst) Legend Biotech
    [Show full text]
  • Lilly to Acquire Imclone Systems in $6.5 Billion Transaction
    Lilly to Acquire ImClone Systems in $6.5 Billion Transaction Creates a Global Leader in Oncology Biopharmaceuticals Boosts Oncology Pipeline With Up to Three Promising Targeted Therapies in Phase III in 2009 INDIANAPOLIS and NEW YORK, Oct 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) and ImClone Systems Inc. (Nasdaq: IMCL) today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion. The offer represents a premium of 51 percent to ImClone's closing stock price on July 30, 2008, the day before an acquisition offer for ImClone was made public. ImClone's board recommends that ImClone's shareholders tender their shares in the tender offer. Additionally, certain entities associated with ImClone's chairman, Carl C. Icahn, holding approximately 14 percent of ImClone's outstanding common stock, have agreed to tender their shares in the tender offer. This strategic combination will create one of the leading oncology franchises in the biopharmaceutical industry, offering both targeted therapies and oncolytic agents along with a pipeline spanning all phases of clinical development. The combined oncology portfolio will target a broader array of solid tumor types including lung, breast, ovarian, colorectal, head and neck, and pancreatic, positioning Lilly to pursue treatments of multiple cancers. Combining with ImClone will further strengthen Lilly's growing portfolio of first-in-class and best-in-class pharmaceutical products, enabling Lilly to better support oncologists, with the ultimate goal of delivering better outcomes for cancer patients.
    [Show full text]